​

Medpace (MEDP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MEDP Stock Forecast

Medpace (MEDP) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $598.89, with a high of $692.00 and a low of $515.00. This represents a -0.41% decline from the last price of $601.38.

$300 $380 $460 $540 $620 $700 High: $692 Avg: $598.89 Low: $515 Last Closed Price: $601.38

MEDP Stock Rating

Medpace stock's rating consensus is Hold, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (21.05%), 14 Hold (73.68%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Hold
Total 19 0 1 14 4 Strong Sell Sell Hold Buy Strong Buy

MEDP Price Target Upside V Benchmarks

TypeNameUpside
StockMedpace-0.41%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks9.24%

Price Target Trends

1M3M12M
# Anlaysts101027
Avg Price Target$598.40$598.40$555.85
Last Closing Price$601.38$601.38$601.38
Upside/Downside-0.50%-0.50%-7.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 261381-13
Jun, 26138-113
May, 26138-113
Apr, 261381-13
Mar, 26-371213
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 24, 2026Ryan HalstedRBC Capital$692.00$601.7315.00%15.07%
Jul 24, 2026Mizuho Securities$665.00$605.829.77%10.58%
Jul 24, 2026BMO Capital$600.00$605.82-0.96%-0.23%
Jul 24, 2026Robert W. Baird$624.00$605.823.00%3.76%
Jul 23, 2026Luke SergottBarclays$600.00$605.82-0.96%-0.23%
Jul 23, 2026Leerink Partners$620.00$605.822.34%3.10%
Jul 23, 2026Deutsche Bank$535.00$603.00-11.28%-11.04%
Jul 13, 2026Mizuho Securities$586.00$538.238.88%-2.56%
Jul 08, 2026Eric ColdwellRobert W. Baird$547.00$546.290.13%-9.04%
Jul 07, 2026David WindleyJefferies$515.00$565.09-8.86%-14.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 24, 2026RBC CapitalOutperformOutperformhold
Jul 24, 2026BMO CapitalMarket PerformMarket Performhold
Jul 24, 2026Cowen & Co.HoldHoldhold
Jul 23, 2026Deutsche BankHoldHoldhold
Jul 07, 2026JefferiesBuyHolddowngrade
Jul 07, 2026RBC CapitalOutperformOutperformdowngrade
Apr 24, 2026RBC CapitalOutperformOutperformhold
Mar 03, 2026RBC CapitalSector PerformOutperforminitialise
Feb 18, 2026Cowen & Co.SellHoldupgrade
Feb 13, 2026JefferiesHoldBuyupgrade

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.06$7.57$9.20$13.06$15.64---
Avg Forecast$4.78$6.97$8.64$11.94$12.52$14.32$16.54$18.08
High Forecast$4.94$7.34$8.97$12.02$12.68$15.97$17.31$18.76
Low Forecast$4.56$6.85$8.63$11.84$12.28$13.57$15.84$17.75
Surprise %5.86%8.61%6.48%9.38%24.92%---

Revenue Forecast

$1B $2B $2B $3B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.14B$1.46B$1.89B$2.11B$2.53B---
Avg Forecast$1.14B$1.45B$1.89B$2.11B$2.21B$2.46B$2.76B$3.14B
High Forecast$1.17B$1.51B$1.94B$2.17B$2.22B$2.48B$2.76B$3.23B
Low Forecast$1.10B$1.43B$1.86B$2.08B$2.20B$2.43B$2.75B$3.09B
Surprise %-0.04%0.56%-0.02%0.12%14.68%---

Net Income Forecast

$100M $200M $300M $400M $500M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$181.85M$245.37M$282.81M$404.39M$451.12M---
Avg Forecast$159.74M$178.50M$282.62M$379.75M$403.41M$458.58M$527.76M$575.69M
High Forecast$191.68M$214.20M$339.14M$382.61M$403.71M$508.54M$551.09M$597.27M
Low Forecast$127.79M$142.80M$226.10M$376.88M$390.88M$432.23M$504.43M$565.27M
Surprise %13.84%37.46%0.07%6.49%11.83%---

MEDP Forecast FAQ

Is Medpace stock a buy?

Medpace stock has a consensus rating of Hold, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 14 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Medpace is a neutral investment for most analysts.

What is Medpace's price target?

Medpace's price target, set by 19 Wall Street analysts, averages $598.89 over the next 12 months. The price target range spans from $515 at the low end to $692 at the high end, suggesting a potential -0.41% change from the previous closing price of $601.38.

How does Medpace stock forecast compare to its benchmarks?

Medpace's stock forecast shows a -0.41% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (9.24%).

What is the breakdown of analyst ratings for Medpace over the past three months?

  • July 2026: 7.69% Strong Buy, 23.08% Buy, 61.54% Hold, 7.69% Sell, 0% Strong Sell.
  • June 2026: 7.69% Strong Buy, 23.08% Buy, 61.54% Hold, 0% Sell, 7.69% Strong Sell.
  • May 2026: 7.69% Strong Buy, 23.08% Buy, 61.54% Hold, 0% Sell, 7.69% Strong Sell.

What is Medpace’s EPS forecast?

Medpace's average annual EPS forecast for its fiscal year ending in December 2026 is $14.32, marking a -8.44% decrease from the reported $15.64 in 2025. Estimates for the following years are $16.54 in 2027, and $18.08 in 2028.

What is Medpace’s revenue forecast?

Medpace's average annual revenue forecast for its fiscal year ending in December 2026 is $2.46B, reflecting a -2.85% decrease from the reported $2.53B in 2025. The forecast for 2027 is $2.76B, and $3.14B for 2028.

What is Medpace’s net income forecast?

Medpace's net income forecast for the fiscal year ending in December 2026 stands at $458.58M, representing an 1.65% increase from the reported $451.12M in 2025. Projections indicate $527.76M in 2027, and $575.69M in 2028.